Daniel Young, PhD Image

Daniel Young, PhD

is an attorney with Wolf Greenfield. Dr. Young works with clients across a broad range of technology areas to develop and implement IP strategies that are aligned with their business goals through portfolio management, patent prosecution, due diligence support, and third-party IP evaluations, focusing primarily in the areas of cell-based therapies, nucleic acid-based therapies, immuno-oncology approaches, antibodies, vaccines, gene therapies, genomics and bioinformatics, biomedical devices, marine and clean energy technologies. For more information, or to contact Dr. Young, please visit his firm profile page.

Recent Articles by Daniel Young, PhD

USPTO Provides Updates to Patent Subject Matter Eligibility Guidance

On its face, the new guidance seems to urge examiners to develop well-reasoned, substantive rejections rather than conclusory rejections which provide little basis for applicants to advance applications toward allowance, particularly in the complex areas of vaccines, diagnostics, methods of treatment, and screening for genetic alterations, where the new examples are focused. Furthermore, compared with prior guidance, the new examples include more claims that are considered patent eligible subject matter. Some observers believe this may be an effort by the patent office to dispel hesitation that examiners have apparently had in drawing conclusions of patent eligibility when examining claims.